Sponsors › University Health Network Toronto

University Health Network Toronto

Every GLP‑1 and incretin trial, approval and scheduled result we hold for University Health Network Toronto, drawn from ClinicalTrials.gov and Drugs@FDA.

University Health Network Toronto is an academic or hospital sponsor, not a drug company with 8 trials in the incretin class on file here, across 3 molecules. The programme is split between 5 early-stage trials and 3 in phase 3 or later. The next scheduled result is 2026-12.

Molecules: exenatide · liraglutide · semaglutide
Trials on file: 8
Active trials: 3
Results scheduled: 0
Approved FDA submissions: 0

Trials on file

All 8 incretin trials recorded for this sponsor, active first.

Drug	Trial	Status	Phase	Participants
semaglutide	Semaglutide vs Sitagliptin NCT05195944	Active, not recruiting	P4	58
semaglutide	Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus NCT06913023	Not yet recruiting	P2/P3	37
semaglutide	The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients NCT05938712	Recruiting	P2	20
exenatide	Exenatide for Myocardial Protection During Reperfusion Study NCT01938235	Unknown	P2	198
semaglutide	Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder NCT04466345	Completed	P2	72
liraglutide	Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial NCT04535960	Unknown	P2	36
liraglutide	Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists NCT02423824	Completed	P3	21
liraglutide	Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study NCT02472717	Withdrawn	P2	—